CagriSema is an investigational combination; the rates below come from its supervised trials of pharmaceutical-grade product with slow dose escalation. This page is educational and does not replace clinical guidance.
Overview
CagriSema's side effects are, overwhelmingly, gastrointestinal. In the 68-week REDEFINE 1 phase 3 trial, 79.6% of participants on the combination reported GI adverse events — nausea, vomiting, diarrhea, constipation, or abdominal pain — versus 39.9% on placebo, though these were mostly transient and mild-to-moderate (NEJM 2025). That headline pairs with the efficacy headline: the same trial produced 20.4% average weight loss. The honest framing is a trade documented in unusual detail — REDEFINE 1 tracked 3,417 participants across four arms (combination, each monotherapy, placebo) for 68 weeks — not a hidden danger and not a free lunch.
The phase 3 numbers
Across the published program:
- REDEFINE 1 (n=3,417, 68 weeks): GI adverse events in 79.6% on CagriSema vs 39.9% on placebo; predominantly transient, mild-to-moderate, and clustered around dose escalation (NEJM 2025).
- Phase 2, type 2 diabetes (n=92, 32 weeks): adverse events in 68% on CagriSema — numerically no worse than semaglutide alone (71%) or cagrilintide alone (80%) in this small sample; mild-to-moderate GI events were most common, with no severe hypoglycemia and no deaths (Lancet 2023).
- Phase 1b (n=96, 20 weeks): GI disorders accounted for 37% of all adverse events; the combination was judged well tolerated with an acceptable safety profile (Lancet 2021).
Two mechanisms, one gut
Both components slow gastric emptying — semaglutide through GLP-1 receptors, cagrilintide through amylin receptors — and both suppress appetite centrally. Stacking them is what produces the exceptional weight loss, and it is also why nearly four in five trial participants felt it in their digestion. The mitigation used in trials was time: sixteen-plus weeks of stepwise escalation before full dose. The interesting phase 2 detail is that the combination did not obviously out-punish its components on tolerability — adverse-event rates were in the same range as either drug alone — but the definitive read on that comes from the larger REDEFINE dataset as it is fully analyzed.
Class-level cautions carried over from GLP-1s
Because half of CagriSema is semaglutide, the GLP-1 class cautions apply to it: gallbladder events, pancreatitis risk, the thyroid C-cell tumor boxed-warning question from rodent data, delayed gastric emptying's interaction with other oral drugs, and attention to hypoglycemia when combined with insulin or sulfonylureas in diabetes. Amylin agonism adds its own appetite-and-gut biology on top. None of these appeared as new signals in the published CagriSema trials, but a combination inherits its parents' open questions rather than erasing them — and adds one of its own, since only the fixed pairing, not every conceivable ratio, has been tested at scale.
What is not yet answered
CagriSema is not approved, so no regulator has yet issued the label that would consolidate its risk profile; longer-term and rare-event data are still accumulating from the REDEFINE program. And outside trials, the practical risk is different in kind: gray-market vials sold under this name are unverified in identity, ratio, and sterility — two molecules' worth of uncertainty in one syringe. For how the trials dosed the real product, see the dosing-education page.